Meyer Handelman Co. Has $41.33 Million Holdings in Gilead Sciences, Inc. $GILD

Meyer Handelman Co. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 336,724 shares of the biopharmaceutical company’s stock after selling 10,645 shares during the quarter. Gilead Sciences accounts for approximately 1.3% of Meyer Handelman Co.’s investment portfolio, making the stock its 21st largest position. Meyer Handelman Co.’s holdings in Gilead Sciences were worth $41,330,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC raised its position in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Gilead Sciences by 8.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 89,670 shares of the biopharmaceutical company’s stock worth $9,942,000 after purchasing an additional 7,080 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its stake in Gilead Sciences by 13,018.2% during the second quarter. Loomis Sayles & Co. L P now owns 55,621 shares of the biopharmaceutical company’s stock worth $6,167,000 after purchasing an additional 55,197 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GILD. Leerink Partners lifted their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. TD Cowen raised their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Stock Up 2.2%

Shares of NASDAQ:GILD opened at $139.37 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a market capitalization of $172.99 billion, a PE ratio of 20.59, a price-to-earnings-growth ratio of 1.79 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a fifty day moving average of $144.62 and a 200-day moving average of $129.06.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is 48.45%.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the transaction, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.